These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
38 related articles for article (PubMed ID: 13519397)
1. [Subcutaneous heparin treatment in cardiosclerosis]. VON AHN B Sven Lakartidn; 1957 Dec; 54(52):3945-55. PubMed ID: 13519397 [No Abstract] [Full Text] [Related]
2. [Use of heparin in the treatment of coronary diseases; heparin in coronary diseases except infarct]. CAMERON-CURRY V Minerva Med; 1957 Jan; 48(6):183-7. PubMed ID: 13418464 [No Abstract] [Full Text] [Related]
3. [Experience with discontinuous heparin in coronary insufficiency]. SAN-CRISTOBAL D; SEPULVEDA G Rev Med Chil; 1953 Nov; 81(11):662-5. PubMed ID: 13156131 [No Abstract] [Full Text] [Related]
4. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease. Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576 [TBL] [Abstract][Full Text] [Related]
5. [Effects of heparin in arteriosclerotic coronary diseases]. SCHIROSA G; GUARINI G Atti Soc Ital Cardiol; 1956; 1():119-21. PubMed ID: 13328642 [No Abstract] [Full Text] [Related]
13. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. Moser LR; Kalus JS Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140 [TBL] [Abstract][Full Text] [Related]
14. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Sinnaeve PR; Simes J; Yusuf S; Garg J; Mehta S; Eikelboom J; Bittl JA; Serruys P; Topol EJ; Granger CB Eur Heart J; 2005 Nov; 26(22):2396-403. PubMed ID: 16214829 [TBL] [Abstract][Full Text] [Related]
15. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2. Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease. Munro A; English C Emerg Med J; 2008 May; 25(5):287-9. PubMed ID: 18434466 [No Abstract] [Full Text] [Related]
16. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Brogan GX; Peterson ED; Mulgund J; Bhatt DL; Ohman EM; Gibler WB; Pollack CV; Farkouh ME; Roe MT Diabetes Care; 2006 Jan; 29(1):9-14. PubMed ID: 16373888 [TBL] [Abstract][Full Text] [Related]
17. A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype. Ray KK; Francis S; Crossman DC J Thromb Haemost; 2005 Feb; 3(2):287-91. PubMed ID: 15670034 [TBL] [Abstract][Full Text] [Related]
18. Use of heparins in Non-ST-elevation acute coronary syndromes. Gore JM; Spencer FA; Goldberg RJ; Kennelly BM; Fox KA; Allegrone J; Eagle KA; Anderson FA; Steg PG; Am J Med; 2007 Jan; 120(1):63-71. PubMed ID: 17208081 [TBL] [Abstract][Full Text] [Related]